Literature DB >> 22720278

Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Melanie D Beaton1.   

Abstract

Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. It is a cause of end-stage liver disease, with increased mortality secondary to cirrhosis and its complications. It is also recognized that cardiovascular disease is a significant cause of death in these patients. Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. The present article reviews the current status of various treatment modalities evaluated in nonalcoholic fatty liver disease.

Entities:  

Mesh:

Year:  2012        PMID: 22720278      PMCID: PMC3378283          DOI: 10.1155/2012/725468

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  70 in total

1.  Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Silvia Fargion
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

2.  Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Authors:  Jeffrey D Browning
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

Review 3.  Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Authors:  F Angelico; M Burattin; C Alessandri; M Del Ben; F Lirussi
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

5.  Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Authors:  Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano
Journal:  JAMA       Date:  2008-11-09       Impact factor: 56.272

6.  A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

Authors:  Austin Nelson; Dawn M Torres; Ana E Morgan; Christopher Fincke; Stephen A Harrison
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

Review 7.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

Authors:  Rajasekhara R Mummadi; Krishna S Kasturi; Swapna Chennareddygari; Gagan K Sood
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

8.  Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.

Authors:  Manal F Abdelmalek; Schuyler O Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J McClain; Keith D Lindor
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

9.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

10.  Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

Authors:  Debora Williams-Herman; Elizabeth Round; Arlene S Swern; Bret Musser; Michael J Davies; Peter P Stein; Keith D Kaufman; John M Amatruda
Journal:  BMC Endocr Disord       Date:  2008-10-27       Impact factor: 2.763

View more
  18 in total

Review 1.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

Authors:  Giada Sebastiani; Peter Ghali; Phil Wong; Marina B Klein; Marc Deschenes; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2014-01

3.  Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.

Authors:  N A Rajesh; L Drishya; Murali Mohan Raju Ambati; Athi L Narayanan; Maria Alex; Kiran Kumar R; Justin J Abraham; T M Vijayakumar
Journal:  J Clin Exp Hepatol       Date:  2021-04-09

4.  Sasa borealis stem extract attenuates hepatic steatosis in high-fat diet-induced obese rats.

Authors:  Yuno Song; Soo-Jung Lee; Sun-Hee Jang; Ji Hee Ha; Young Min Song; Yeoung-Gyu Ko; Hong-Duck Kim; Wongi Min; Suk Nam Kang; Jae-Hyeon Cho
Journal:  Nutrients       Date:  2014-06-05       Impact factor: 5.717

5.  Ruscogenin ameliorates experimental nonalcoholic steatohepatitis via suppressing lipogenesis and inflammatory pathway.

Authors:  Hung-Jen Lu; Thing-Fong Tzeng; Shorong-Shii Liou; Chia Ju Chang; Cheng Yang; Ming-Chang Wu; I-Min Liu
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 6.  Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects.

Authors:  Ravirajsinh Jadeja; Ranjitsinh V Devkar; Srinivas Nammi
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-03       Impact factor: 2.629

7.  White Pitaya (Hylocereus undatus) Juice Attenuates Insulin Resistance and Hepatic Steatosis in Diet-Induced Obese Mice.

Authors:  Haizhao Song; Zihuan Zheng; Jianan Wu; Jia Lai; Qiang Chu; Xiaodong Zheng
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

8.  Leonurus japonicus Houtt Attenuates Nonalcoholic Fatty Liver Disease in Free Fatty Acid-Induced HepG2 Cells and Mice Fed a High-Fat Diet.

Authors:  Mi-Ra Lee; Kwang Il Park; Jin Yeul Ma
Journal:  Nutrients       Date:  2017-12-25       Impact factor: 5.717

Review 9.  Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.

Authors:  Che-Yung Chao; Robert Battat; Alex Al Khoury; Sophie Restellini; Giada Sebastiani; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

10.  Mapping of fatty acid composition with free-breathing MR spectroscopic imaging and compressed sensing.

Authors:  James A Rioux; Miriam Hewlett; Christa Davis; Chris V Bowen; Kimberly Brewer; Sharon E Clarke; Steven D Beyea
Journal:  NMR Biomed       Date:  2020-01-03       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.